Boehringer Ingelheim registers Phase 1 bioavailability study for BI 3034701
A new crossover trial comparing two subcutaneous formulations of BI 3034701 in healthy volunteers is recruiting at a single UK site.
Boehringer Ingelheim had one trial update this week involving its investigational compound BI 3034701.
- A Phase 1 trial, "Relative Bioavailability of Two Different BI 3034701 Treatments Following Subcutaneous Administration in Healthy Male and Female Participants," is an open-label, randomized, single-dose, two-period, two-sequence crossover study comparing BI 3034701 treatment T against treatment R.1 The study is recruiting, with an actual start date of 2026-10-05 and an estimated primary completion date of 2026-12-15.1 It plans to enroll 30 participants1 and is running at one site, Quotient Sciences in Nottingham, United Kingdom.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.